Philippe Chanson

Université Paris-Saclay
Country flagFrance

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (21)

Year:

2025

Year:

2025

Year:

2025

Context Outcome of craniopharyngioma is related to its locoregional extension, which impacts resectability and the risk of surgical complications. To maximize resection and minimize complications, optic tract localization, temporal lobe extension, and hypothalamic involvement are essential factors for surgical management. Objective To assess the outcome of craniopharyngiomas depending on their relation to the hypothalamus location. Methods We conducted a retrospective analysis of 79 patients with a craniopharyngioma who underwent surgery from 2007 to 2022. Craniopharyngiomas were classified in 3 groups, depending on the type of hypothalamus involvement assessed by preoperative magnetic resonance imaging: infra-hypothalamic (type A, n = 33); perforating the hypothalamus (type B, n = 40); and supra-hypothalamic (type C, n = 6). Surgical strategy was guided by the type of hypothalamic involvement, favoring endonasal approaches for type A and type B, and transcranial approaches for type C. Results Long-term disease control was achieved in 33/33 (100%), 37/40 (92%), and 5/6 (83%) patients in type A, B, and C, respectively. In type B, vision was improved in 32/36 (89%) patients, while hypothalamic function was improved, stable, or worsened in 6/40 (15%), 32/40 (80%), and 2/40 (5%) patients, respectively. Papillary craniopharyngiomas were found in 5/33 (15%), 9/40 (22%), and 3/6 (50%) patients in types A, B, and C, respectively. In 4 patients, BRAF/MEK inhibitors were used, with significant tumor shrinkage in all cases. Conclusion Craniopharyngiomas located below the hypothalamus or perforating it can be safely treated by transsphenoidal surgery. For supra-hypothalamic craniopharyngiomas, postoperative results are less favorable, and documenting a BRAF mutation may improve outcome, if targeted therapy was efficient enough to replace surgical debulking.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (12)

Peter Kamenický

Université Paris-Saclay

FRANCE
View details

Jacques Young

Université Paris-Saclay

FRANCE
View details

Georgios E. Papadakis

Senior Lecturer : Privat-Docent (PD) & Maître d'Enseignement et Recherche (MERclin)

University of Lausanne

SWITZERLAND
View details

Emmanuel DURAND

Professor

Université Paris-Saclay

FRANCE
View details

Bertrand Baussart

-

FRANCE
View details

Gerald Raverot

Professor

Hospices Civils de Lyon

FRANCE
View details

Pamela U Freda

-

UNITED STATES
View details

Albert Beckers

University of Liege

BELGIUM
View details

Antoine Tabarin

-

FRANCE
View details

Nienke Biermasz

Professor of Internal Medicine

Leiden University Medical Center

NETHERLANDS
View details

Ariel Barkan

University of Michigan

UNITED STATES
View details

Peter Wolf

Medical University of Vienna

AUSTRIA
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.